Inside MedSpa — Never miss a recall or a rule change.
Today's Medspa Watch — Sep 24, 2026
Devices & Tech
Sofwave Gets China Approval—New Market Entry
Business & M&A
Galderma Plants Flag in Miami—Aesthetic Capital Expansion Signals Growth Play
Injectables
Korean Injectable Makers Eye U.S. Market—Skin Booster Competition Heats Up
Devices & Tech
Candela Laser Systems Deployed at Menlo Park Practice—Nordlys and GentleMax Pro Plus
Devices & Tech
TRIANGEL Launches ENDOLASER Plus—RF Microneedling for Body Tightening
Why this exists
They're not smarter than you. They just read the filings.
Every week the FDA clears a device, a state board rewrites who can inject what, a manufacturer quietly changes its pricing. None of it is secret — the clearances, the enforcement actions, the rule changes are all published, all public, and buried in databases no practice owner has time to check. Device reps and consultants have staff for that. Now you have us.
How Inside MedSpa works →Latest Across the Industry
All coverage →-
Business & M&A
Galderma Joins Swiss Market Index—Valuation Milestone
Galderma's SMI inclusion reflects market confidence and signals institutional investor appetite for aesthetics.
-
Business & M&A
Galderma Raises Full-Year 2026 Earnings Guidance
Stronger-than-expected H1 performance prompts upward revision of profit outlook.
-
Compliance
Counterfeit Laser Devices Recalled in Canada
Health Canada flags serious health risks from fake laser therapy systems circulating in clinics.
-
Regulatory
Revance Liquid Botox Hits Manufacturing Roadblock
FDA issues Complete Response Letter for liquid botulinum toxin over manufacturing compliance issues.
-
Injectables
Hugel Targets Direct U.S. Toxin Launch in Late 2027
South Korean manufacturer bets on independent U.S. distribution for its neuromodulator—a direct challenge to AbbVie and Galderma.
-
Devices & Tech
Alma Lasers Launches Accent Prime in India
RF microneedling device enters Gurugram market for body contouring and skin tightening.
-
Business & M&A
Evolus Posts Positive Q2 2026 EPS at $0.02
Neuromodulator manufacturer beats earnings estimates by 157%, signaling margin recovery.
-
Injectables
Galderma's Restylane Volyme Wins China Temple Study
Clinical data shows high efficacy and safety in Chinese patients with temple hollowing.
-
Market
Allergan's GLP-1 Skin Study: What Practices Need to Know
AbbVie's Allergan Aesthetics released clinical data on skin quality in weight-loss drug users—and the implications for your patient base are real.
Why owners trust it
See exactly how we source & verify →
Primary sources. No agenda. Verified before it runs.
Straight from the recordFDA, SEC EDGAR, the Federal Register, and state boards — read directly, not rehashed from blogs.
Independent by designWe sell no devices, software, or financing — so the take answers to you, never an advertiser.
AI speed, verified factsA purpose-built engine reads everything; a verification step holds anything that doesn’t trace to a source.
Owners onlyFiltered to one test: does this touch your money, your license, or your patients’ demand?